Endocrine Pharmacology
Obesity is a chronic metabolic disease characterized by excessive adipose tissue accumulation, quantified by body mass index (BMI) of 30 kg/m² or greater. This condition results from complex interactions between genetic predisposition, environmental factors, neuroendocrine dysregulation, and behavioral patterns. Pharmacologic management is indicated for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia) when lifestyle interventions alone prove insufficient. Contemporary pharmacotherapy targets appetite regulation, nutrient absorption, and satiety signaling to achieve clinically significant weight loss of 5% to 15% total body weight.
📋 Abbreviations Used in This Article
- BMI: Body Mass Index
- GLP-1: Glucagon-Like Peptide-1
- GIP: Glucose-Dependent Insulinotropic Polypeptide
- GI: Gastrointestinal
- OTC: Over-The-Counter
- MAOI: Monoamine Oxidase Inhibitor
- BP: Blood Pressure
🎯 Treatment Indications
BMI-based classification guides pharmacotherapy decisions:
| Classification | BMI (kg/m²) | Health Risk | Pharmacotherapy Indication |
|---|---|---|---|
| Normal Weight | 18.5 to 24.9 | Lowest | Not indicated |
| Overweight | 25 to 29.9 | Increased | With comorbidities only |
| Obesity Class I | 30 to 34.9 | High | Generally indicated |
| Obesity Class II | 35 to 39.9 | Very High | Strongly indicated |
| Obesity Class III | ≥40 | Extremely High | Indicated; consider surgery |
🎯 Treatment Threshold: Pharmacotherapy considered for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) despite 3 to 6 months of intensive lifestyle intervention.
💊 Pharmacologic Agents
Multiple drug classes target different mechanisms of weight regulation:
| Agent | Mechanism | Average Weight Loss | Key Adverse Effects |
|---|---|---|---|
| Phentermine | Appetite suppression (sympathomimetic) | 3% to 5% at 6 months | Tachycardia, hypertension, insomnia |
| Orlistat | Pancreatic lipase inhibition | 2.5% to 3.5% at 1 year | Steatorrhea, fat-soluble vitamin deficiency |
| Liraglutide 3.0 mg | GLP-1 receptor agonist | 8% to 10% at 1 year | Nausea, vomiting, pancreatitis risk |
| Semaglutide 2.4 mg | GLP-1 receptor agonist | 12% to 15% at 1 year | GI effects, gallbladder disease |
| Tirzepatide | Dual GIP/GLP-1 agonist | 15% to 20% at 1 year | GI effects, injection site reactions |
| Naltrexone/Bupropion | Central appetite regulation | 4% to 5% at 1 year | Nausea, headache, increased BP |
| Phentermine/Topiramate | Appetite suppression, satiety | 7% to 9% at 1 year | Paresthesia, teratogenicity |
🎯 Appetite Suppressants
Sympathomimetic agents reducing hunger through hypothalamic norepinephrine release:
Phentermine
- Dosing: 15 to 37.5 mg daily before breakfast
- Schedule: IV controlled substance
- Duration: FDA-approved for short-term use (typically 3 to 6 months)
- Contraindications: Cardiovascular disease, uncontrolled hypertension, hyperthyroidism
Monitoring Requirements
- Blood pressure and heart rate at each visit
- Screen for abuse potential
- Avoid MAOI use within 14 days
- Assess for cardiovascular symptoms
🔬 Lipase Inhibitor
Orlistat reduces dietary fat absorption through local gastrointestinal action:
Orlistat (Xenical, Alli)
- Mechanism: Inhibits gastric and pancreatic lipases, reducing fat absorption by approximately 30%
- Prescription: 120 mg three times daily with fat-containing meals
- OTC: Alli 60 mg three times daily with meals
- Supplementation: Fat-soluble vitamins (A, D, E, K) at least 2 hours before or after orlistat
- Adverse Effects: Oily spotting, fecal urgency, flatus with discharge (reduced with low-fat diet less than 30% calories from fat)
💉 GLP-1 Receptor Agonists
Incretin-based therapies with superior efficacy for weight reduction:
Liraglutide (Saxenda)
- Dosing: Titrate from 0.6 mg to 3.0 mg daily subcutaneously
- Titration: Increase by 0.6 mg weekly over 5 weeks
- Administration: Daily injection
Semaglutide (Wegovy)
- Dosing: Titrate from 0.25 mg to 2.4 mg weekly subcutaneously
- Titration: Monthly dose escalation over 16 to 20 weeks
- Administration: Weekly injection
- Efficacy: Most effective single-agent pharmacotherapy
⚠️ Black Box Warning: GLP-1 receptor agonists cause thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
🔄 Combination Therapies
Fixed-dose combinations targeting multiple pathways:
| Combination | Components | Dosing | Special Considerations |
|---|---|---|---|
| Naltrexone/Bupropion (Contrave) | Naltrexone 8 mg + Bupropion 90 mg per tablet | Titrate to 2 tablets twice daily | Contraindicated in seizure disorders, eating disorders |
| Phentermine/Topiramate (Qsymia) | Variable strengths; gradual titration | Multiple dose levels available | Pregnancy prevention program mandatory (teratogenic) |
📊 Treatment Algorithm
Systematic approach to pharmacotherapy selection and monitoring:
Step-Wise Management Protocol
- Step 1 - Assessment: BMI calculation, comorbidity evaluation, medication history review
- Step 2 - Lifestyle Intervention: 3 to 6 months intensive diet, exercise, behavioral modification
- Step 3 - Pharmacotherapy Initiation: If less than 5% weight loss with lifestyle alone
- Step 4 - Drug Selection Based On:
- Comorbidities (GLP-1 agonists for diabetes)
- Efficacy requirements (semaglutide for maximum weight loss)
- Route preference (oral versus injection)
- Cost and insurance coverage
- Step 5 - Efficacy Assessment at 3 Months:
- Continue if ≥5% weight loss and well-tolerated
- Discontinue or switch if less than 5% weight loss
- Consider combination or alternative therapy
🎯 Long-Term Management: Obesity is a chronic disease requiring indefinite pharmacotherapy. Weight regain is common upon medication discontinuation. Continued therapy warranted as long as benefits outweigh risks with regular reassessment every 3 to 6 months.
🎯 Clinical Pearls
Essential high-yield principles for obesity pharmacotherapy:
- Pharmacotherapy is adjunct to lifestyle modification, never replacement
- Semaglutide and tirzepatide provide greatest weight loss (12% to 20%)
- GLP-1 agonists contraindicated with personal/family history of medullary thyroid cancer or MEN 2
- Orlistat requires fat-soluble vitamin supplementation separated by 2 hours
- Phentermine is Schedule IV controlled substance; short-term use only
- Discontinue medication if less than 5% weight loss at 3 months
- Weight loss of 5% to 10% significantly improves metabolic health
- Monitor blood pressure, heart rate with sympathomimetics
- Phentermine/topiramate requires pregnancy prevention (teratogenic)
- Consider bariatric surgery for BMI ≥40 or BMI ≥35 with comorbidities
🔬 Pharmacology Study Tips:
- Mechanism categories: Appetite suppression (phentermine), absorption inhibition (orlistat), satiety enhancement (GLP-1 agonists)
- Efficacy ranking: Tirzepatide > Semaglutide > Liraglutide > Phentermine/Topiramate > Others
- Route distinction: Injectable (GLP-1 agonists) versus oral (all others)
- Remember contraindications: Cardiovascular disease (phentermine), thyroid cancer (GLP-1s), seizures (bupropion)
💉 GLP-1 Receptor Agonists
Incretin-based therapies with superior efficacy for weight reduction:
Liraglutide (Saxenda)
- Dosing: Titrate from 0.6 mg to 3.0 mg daily subcutaneously
- Titration: Increase by 0.6 mg weekly over 5 weeks
- Administration: Daily injection
Semaglutide (Wegovy)
- Dosing: Titrate from 0.25 mg to 2.4 mg weekly subcutaneously
- Titration: Monthly dose escalation over 16 to 20 weeks
- Administration: Weekly injection
- Efficacy: Most effective single-agent pharmacotherapy
⚠️ Black Box Warning: GLP-1 receptor agonists cause thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
🔄 Combination Therapies
Fixed-dose combinations targeting multiple pathways:
| Combination | Components | Dosing | Special Considerations |
|---|---|---|---|
| Naltrexone/Bupropion (Contrave) | Naltrexone 8 mg + Bupropion 90 mg per tablet | Titrate to 2 tablets twice daily | Contraindicated in seizure disorders, eating disorders |
| Phentermine/Topiramate (Qsymia) | Variable strengths; gradual titration | Multiple dose levels available | Pregnancy prevention program mandatory (teratogenic) |
📊 Treatment Algorithm
Systematic approach to pharmacotherapy selection and monitoring:
Step-Wise Management Protocol
- Step 1 - Assessment: BMI calculation, comorbidity evaluation, medication history review
- Step 2 - Lifestyle Intervention: 3 to 6 months intensive diet, exercise, behavioral modification
- Step 3 - Pharmacotherapy Initiation: If less than 5% weight loss with lifestyle alone
- Step 4 - Drug Selection Based On:
- Comorbidities (GLP-1 agonists for diabetes)
- Efficacy requirements (semaglutide for maximum weight loss)
- Route preference (oral versus injection)
- Cost and insurance coverage
- Step 5 - Efficacy Assessment at 3 Months:
- Continue if ≥5% weight loss and well-tolerated
- Discontinue or switch if less than 5% weight loss
- Consider combination or alternative therapy
🎯 Long-Term Management: Obesity is a chronic disease requiring indefinite pharmacotherapy. Weight regain is common upon medication discontinuation. Continued therapy warranted as long as benefits outweigh risks with regular reassessment every 3 to 6 months.
🎯 Clinical Pearls
Essential high-yield principles for obesity pharmacotherapy:
- Pharmacotherapy is adjunct to lifestyle modification, never replacement
- Semaglutide and tirzepatide provide greatest weight loss (12% to 20%)
- GLP-1 agonists contraindicated with personal/family history of medullary thyroid cancer or MEN 2
- Orlistat requires fat-soluble vitamin supplementation separated by 2 hours
- Phentermine is Schedule IV controlled substance; short-term use only
- Discontinue medication if less than 5% weight loss at 3 months
- Weight loss of 5% to 10% significantly improves metabolic health
- Monitor blood pressure, heart rate with sympathomimetics
- Phentermine/topiramate requires pregnancy prevention (teratogenic)
- Consider bariatric surgery for BMI ≥40 or BMI ≥35 with comorbidities
🔬 Pharmacology Study Tips:
- Mechanism categories: Appetite suppression (phentermine), absorption inhibition (orlistat), satiety enhancement (GLP-1 agonists)
- Efficacy ranking: Tirzepatide > Semaglutide > Liraglutide > Phentermine/Topiramate > Others
- Route distinction: Injectable (GLP-1 agonists) versus oral (all others)
- Remember contraindications: Cardiovascular disease (phentermine), thyroid cancer (GLP-1s), seizures (bupropion)
🎯 Clinical Pearls
Essential high-yield principles for obesity pharmacotherapy:
- Pharmacotherapy is adjunct to lifestyle modification, never replacement
- Semaglutide and tirzepatide provide greatest weight loss (12% to 20%)
- GLP-1 agonists contraindicated with personal/family history of medullary thyroid cancer or MEN 2
- Orlistat requires fat-soluble vitamin supplementation separated by 2 hours
- Phentermine is Schedule IV controlled substance; short-term use only
- Discontinue medication if less than 5% weight loss at 3 months
- Weight loss of 5% to 10% significantly improves metabolic health
- Monitor blood pressure, heart rate with sympathomimetics
- Phentermine/topiramate requires pregnancy prevention (teratogenic)
- Consider bariatric surgery for BMI ≥40 or BMI ≥35 with comorbidities
🔬 Pharmacology Study Tips:
- Mechanism categories: Appetite suppression (phentermine), absorption inhibition (orlistat), satiety enhancement (GLP-1 agonists)
- Efficacy ranking: Tirzepatide > Semaglutide > Liraglutide > Phentermine/Topiramate > Others
- Route distinction: Injectable (GLP-1 agonists) versus oral (all others)
- Remember contraindications: Cardiovascular disease (phentermine), thyroid cancer (GLP-1s), seizures (bupropion)